📄 medicine

Sustained optogenetic expression in skeletal muscle is limited by host adaptive immunity, but preserved with targeted immunosuppression

This study demonstrates that while host adaptive immunity limits sustained optogenetic expression in skeletal muscle for treating obstructive sleep apnea, a combination of rapamycin and cyclosporin effectively mitigates this immune response to preserve durable transgene expression and functional muscle activation.

Original authors: Fiona L. Knapman, Elena Shklovskaya, Ryan Swain, Anita Turner, Nigel H. Lovell, Leszek Lisowski, Peter A. Cistulli, Peter G.R. Burke, Lynne E. Bilston

Published 2026-07-06

📖 4 min read☕ Coffee break read

CC BY 4.0

Original authors: Fiona L. Knapman, Elena Shklovskaya, Ryan Swain, Anita Turner, Nigel H. Lovell, Leszek Lisowski, Peter A. Cistulli, Peter G.R. Burke, Lynne E. Bilston

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

The Big Picture: A Broken Light Switch

Imagine you have a very special light switch (a gene therapy) designed to turn on the muscles in your throat to keep your airway open while you sleep. This is a potential cure for Obstructive Sleep Apnea (OSA), a condition where the throat collapses during sleep, affecting up to a billion people.

Scientists have developed a way to install this "switch" using a harmless virus (called rAAV) that delivers the instructions to the muscle cells. Once installed, shining a specific light on the throat should make the muscles tighten and keep the airway open.

However, there was a major problem: In rats, this "switch" worked great for the first few weeks, but then it stopped working by the 12-week mark. The body's immune system seemed to recognize the new "switch" as an intruder and tore it down.

The Experiment: Trying Different Security Guards

The researchers wanted to know: Can we trick the body's immune system into leaving the new "switch" alone?

They set up an experiment with three groups of rats, all receiving the gene therapy. To protect the therapy, they gave the rats different types of "security guards" (immunosuppressant drugs) to calm down the immune system:

Group A (The Standard Guard): Given Prednisolone. This is a common steroid often used in human trials to calm inflammation. Think of this as a general security guard who tells everyone to "be quiet."
Group B (The Specialized Team): Given a combination of Rapamycin and Cyclosporin. These drugs are more like a specialized SWAT team that specifically targets the immune cells responsible for attacking new proteins.
Group C (No Guard): Given a placebo (vehicle control). These rats had no protection.

The Results: Who Kept the Lights On?

1. The Placebo Group (No Guard)
As expected, the immune system attacked the new "switch." By week 12, the instructions were gone, the muscles didn't respond to light, and the tissue looked damaged and inflamed.

2. The Prednisolone Group (The Standard Guard)
Surprisingly, this didn't work either. Even with the steroid, the immune system still found and destroyed the "switch." By week 12, the results looked almost exactly the same as the group with no guard at all. The muscles were silent, and the tissue showed signs of inflammation and scarring.

3. The Rapamycin/Cyclosporin Group (The Specialized Team)
This group was the winner.

The Lights Stayed On: The "switch" (opsin expression) remained strong and bright for the full 12 weeks.
Muscles Worked: When the researchers shined the light on these rats' tongues, the muscles contracted powerfully, doubling their activity.
Tissue Health: The tissue looked healthy, with very few "invader" immune cells and no signs of scarring or fat replacing the muscle.

The Catch: The Cost of the Specialized Team

While the specialized drug combo worked perfectly to save the therapy, it came with a side effect, but only for the male rats.

The "Metabolic Glitch": The male rats on the special drugs stopped gaining weight, drank a lot more water, and produced more urine. Their blood sugar also went up.
The Females: The female rats on the same drugs did not have these severe side effects; they just gained weight a little slower than usual.
Overall Health: Despite these metabolic changes, all the rats remained active, groomed themselves, and behaved normally. They didn't look sick, just a bit different in how they processed food and water.

The Conclusion

This study proves that you can keep the gene therapy working in muscle tissue, but you need the right kind of immune protection.

Prednisolone (the common steroid) was not strong enough to stop the immune system from deleting the new instructions.
Rapamycin and Cyclosporin (the specialized combo) successfully stopped the immune system, allowing the therapy to work for months.

The researchers conclude that for this type of gene therapy to work in the long term, we likely need to use drugs that specifically target the immune cells that attack new proteins, rather than just using general anti-inflammatory steroids. However, they also noted that the side effects (like changes in weight and water balance) need to be carefully managed, especially since the side effects seemed to affect male rats more than females.

In short: To keep the "light switch" in the throat working, you need a very specific type of bodyguard, not just a generic one. But hiring that specific bodyguard might make the body a little thirsty and hungry.

Technical Summary: Sustained Optogenetic Expression in Skeletal Muscle via Targeted Immunosuppression

Problem Statement
Obstructive sleep apnoea (OSA) is a prevalent condition characterized by upper airway collapse due to inadequate neuromuscular compensation. While optogenetic muscle stimulation offers a promising, precise, and non-invasive therapeutic strategy by directly targeting muscle cells with light-sensitive proteins (opsins), its clinical translation faces a significant barrier: the durability of transgene expression. Previous preclinical studies in rats demonstrated that while recombinant adeno-associated viral (rAAV) vectors could initially drive robust opsin expression in skeletal muscle, this expression was transient, declining significantly between 3 and 12 weeks post-administration. This decline is hypothesized to be driven by host adaptive immune responses against the viral vector and/or the non-endogenous transgene product, a limitation less pronounced in mouse models where expression often persists without intervention.

Methodology
To investigate whether immune-mediated clearance underlies this loss of expression and to test mitigation strategies, the authors conducted a study using Sprague-Dawley rats ( $N=24$ ). The animals were divided into three treatment groups ( $n=8$ per group):

Prednisolone Group: Received systemic prednisolone (1 mg/kg) three times weekly, starting one week prior to viral delivery and tapering over 13 weeks.
Rapamycin/Cyclosporin Group: Received a combination of rapamycin (4 mg/kg) and cyclosporin (5 mg/kg) three times weekly under the same schedule.
Vehicle Control Group: Received equivalent solvent volumes.

All rats received intramuscular injections of an AAV9 vector encoding a channelrhodopsin-2 variant (ChR2(H134R)) fused to an mCherry fluorescent reporter, driven by a muscle-specific creatine kinase promoter (tMCK), into the tongue muscles.

Key Assessments:

Histology: At 12 weeks, tongue tissues were analyzed for mCherry fluorescence (opsin expression), DAPI-positive nuclei (total cell density), and Hematoxylin-positive nuclei (immune cell infiltration). Tissue integrity was assessed via H&E staining to identify fibrosis or adipose deposition.
Functional Assay: Light-evoked muscle activation was measured using electromyography (EMG). Animals were anesthetized to induce a state of upper airway hypotonia, and light stimulation (470 nm) was applied during inspiration to quantify the recovery of muscle activity.
Metabolic Monitoring: Body weight, blood glucose, water consumption, and urine output were monitored to assess the side effects of immunosuppression.

Key Results

Opsin Expression: The rapamycin/cyclosporin group demonstrated significantly sustained opsin expression at 12 weeks. Quantitative analysis showed an 18.4-fold increase in reporter expression compared to the prednisolone group and a 12-fold increase compared to the vehicle control. In contrast, the prednisolone group showed minimal expression, statistically indistinguishable from the vehicle control.
Immune Infiltration and Tissue Integrity: The rapamycin/cyclosporin group exhibited a ~20% reduction in immune cell infiltration (DAPI+ and Hematoxylin+ nuclei density) compared to controls. Histological analysis revealed that vehicle and prednisolone groups displayed signs of chronic inflammation, including dense nuclear clusters, fibrosis, and adipose deposition. These pathological features were largely absent in the rapamycin/cyclosporin group.
Functional Efficacy: Only the rapamycin/cyclosporin group showed significant light-evoked muscle activation, with EMG activity increasing approximately two-fold compared to unstimulated periods. Neither the vehicle nor the prednisolone groups demonstrated a functional response to light stimulation.
Metabolic Side Effects: The immunosuppressive regimen induced sex-specific metabolic changes. Male rats treated with rapamycin/cyclosporin failed to gain weight over the 13-week period and exhibited elevated blood glucose, increased water intake, and polyuria. Female rats showed a slower weight gain trajectory but did not exhibit the same metabolic disturbances. Despite these physiological changes, all animals maintained normal behavioral indicators of health.

Significance and Claims
The authors claim that this study provides the first evidence that targeted immunosuppression using a combination of rapamycin and cyclosporin, but not prednisolone alone, can sustain robust, functional optogenetic expression in rat skeletal muscle for at least 12 weeks.

The paper emphasizes that while prednisolone is a standard prophylactic in clinical rAAV trials, it was insufficient to prevent the loss of transgene expression in this specific context. The success of the rapamycin/cyclosporin regimen suggests that adaptive immunity, specifically T-cell-mediated clearance and potentially B-cell responses, drives the loss of opsin expression in rats.

The authors conclude that these findings support the feasibility of optogenetic muscle stimulation as a gene therapy-based approach for OSA, provided that immune management strategies are optimized. They highlight the critical importance of evaluating rAAV therapies in multiple species, as immune responses vary significantly between mice and rats (and by extension, potentially humans). The study underscores that for non-endogenous transgene products in non-immune-privileged tissues like muscle, immune management is essential for durable therapeutic expression. However, the authors remain modest regarding clinical translation, noting that the risk-benefit profile of such immunosuppression regimens must be carefully weighed, particularly for non-life-threatening conditions like OSA, and that further work is needed to determine minimal effective doses and the durability of expression after treatment withdrawal.